Ovarian Function Following Intraovarian Injection of PRP

Launched by CENTER FOR HUMAN REPRODUCTION · Feb 18, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Platelet Rich Plasma (PRP) to see if it can help improve ovarian function in women who have a low number of eggs, a condition known as diminished ovarian reserve. This can happen for various reasons, including being of advanced maternal age. Women who choose to participate will be randomly assigned to receive either PRP or a control treatment called Platelet Poor Plasma (PPP). The goal is to find out if PRP can help women who are trying to become pregnant through in-vitro fertilization (IVF).

To be eligible for the trial, women must be 44 years old or younger and have had fewer than 6 eggs in previous fertility treatments. They should also have specific hormone levels indicating diminished ovarian reserve. Participants will need to stop taking certain medications, like aspirin, a week before the treatment. The trial is currently recruiting, so if you or someone you know meets the criteria and is interested in exploring this treatment option, it could be a valuable opportunity to help with fertility challenges.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • fewer than 6 oocytes in response to past ovulation induction
• • desire to establish a pregnancy using IVF
• • Age 44 years and under.
• • FSH \> 12
• • AMH \< 1.0
• • No Aspirin or Motrin for one week before treatment
• Exclusion Criteria:
• • Age \> 45 years
• • Marked thrombocytopenia
• • Blood diseases
• • Hypofibrinogenemia
• • Hemodynamic instability
• • Anticoagulant or antiaggregant treatment
• • Oncological diseases (specially, skeletal system and blood)
• • Sepsis
• • Acute and chronic infectious diseases
• • Autoimmune diseases, for example, lupus erythematosus, etc.